IMPACT OF USE OF SGLT2 INHIBITORS ON CONTROL OF ALBUMINURIA AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION

Abstract

Chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) and systemic arterial hypertension (SAH) is a prevalent condition associated with high rates of morbidity and mortality. Sodium-glucose cotransporter type 2 (SGLT2) inhibitors have emerged as an innovative therapeutic class, demonstrating significant renal benefits that go beyond glycemic control. This study aimed to evaluate the impact of SGLT2 inhibitors on reducing albuminuria and CKD progression in patients with T2DM and SAH. Through a comprehensive literature review, clinical trials and observational studies published between 2015 and 2024 were analyzed. The results showed that SGLT2 inhibitors significantly reduce albuminuria levels, slow the decline in glomerular filtration rate, and promote cardiorenal benefits. However, limitations such as reduced efficacy in advanced stages of CKD and access barriers were identified. It is concluded that SGLT2 inhibitors represent a promising strategy in the management of CKD, with the potential to transform the clinical outcomes of patients with T2DM and hypertension.